Risteys · C3_KAPOSI_SARCOMA

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — C46 Cause of death: ICD-10 — C46 2 out of 7 registries used, show all original rules.	61
4. Check minimum number of events None	61
5. Include endpoints None	61
6. Filter based on genotype QC (FinnGen only)	61

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	61	16	45
Unadjusted period prevalence (%)	0.02	0.01	0.02
Median age at first event (years)	72.97	66.89	75.13

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
52: Matched controls
519

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

C46.0

ICD-10 Finland

Kaposi sarcoma of skin

+∞

39.7

9140/3-C44.7

ICD-O-3

Kaposi sarcoma of skin of lower limb and hip

+∞

18.8

C46.9

ICD-10 Finland

Kaposi sarcoma, unspecified

+∞

11.9

QAE10

NOMESCO Finland

Excision of other lesion extending through all layers of skin in head or neck

27.1

8.4

ZX012

NOMESCO Finland

Radiotherapy with large shaped fields - isocentric therapy

+∞

7.4

TQX10

NOMESCO Finland

Biopsy of skin and subcutaneous tissue

10.1

7.2

ZZA00

NOMESCO Finland

Split skin graft

46.0

6.9

D48.5

ICD-10 Finland

Neoplasm of uncertain or unknown behaviour: Skin

15.0

6.4

WF004

NOMESCO Finland

Palliative radiotherapy

+∞

6.4

C46.3

ICD-10 Finland

Kaposi sarcoma of lymph nodes

+∞

6.4

B23.1

ICD-10 Finland

HIV disease resulting in (persistent) generalized lymphadenopathy

+∞

6.4

C46.7

ICD-10 Finland

Kaposi sarcoma of other sites

+∞

6.4

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(4035726)

23.47

11.47

2.1

1.2

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

7.56

10.46

1.7

1.3

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

7.62

7.55

4.6

1.6

—

(40768804) Tissue Pathology biopsy report

104

4.41

7.49

3.9

1.4

—

(3002256) Pathology report gross observation

6.43

7.37

2.4

1.1

—

(3021879) Hepatitis B virus core Ab [Presence] in Serum

8.35

6.92

4.7

1.4

—

(3007853) Bacteria identified in Skin by Aerobe culture

4.36

5.32

1.8

1.9

—

(3019832) Treponema pallidum Ab [Presence] in Serum

9.68

3.88

1.6

1.3

—

(3006140) Bilirubin.total [Moles/volume] in Serum or Plasma

189

2.81

3.79

12.4

3.1

9.9

13.1

umol/l

1.61

178

(3044640) Blood type and Crossmatch panel - Blood

107

2.85

3.55

5.1

2.0

—

(3037121) Protein [Mass/volume] in Urine

6.39

3.47

9.1

2.3

0.4

0.2

g/l

—

(42870588) Differential panel, method unspecified - Blood

117

2.73

3.37

11.0

4.8

—

(3000494) Fungus identified in Specimen by Culture

3.59

3.30

2.4

1.5

—

(40768443) Skin Pathology biopsy report

5.24

3.03

1.6

1.1

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

5.24

3.03

3.7

1.6

—

(3018010) Neutrophils/100 leukocytes in Blood

164

2.46

2.94

14.4

5.1

58.0

59.4

0.26

147

(3008757) Leukocyte morphology finding [Identifier] in Blood

8.93

2.80

4.2

5.8

—

(3042936) Bacteria identified in Isolate by Culture

2.97

2.65

2.4

1.9

—

(3004789) Transferrin [Mass/volume] in Serum or Plasma

2.93

2.44

2.8

2.7

2.3

2.2

g/l

0.12

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

134

2.30

2.42

3.8

3.1

—

(3015736) pH of Urine

143

2.27

2.37

4.8

3.3

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

4.99

2.33

1.7

1.5

—

(3046279) Procalcitonin [Mass/volume] in Serum or Plasma

4.99

2.33

5.7

1.7

0.5

0.7

ug/l

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

146

2.21

2.24

8.8

3.4

—

(3022948) Iron [Moles/volume] in Serum or Plasma

2.68

2.23

2.8

2.5

11.5

12.1

umol/l

0.08

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

3.52

2.18

2.5

1.3

—

(3037467) Urinalysis macro (dipstick) panel - Urine

255

2.15

6.2

4.1

—

(40758558) Short blood count panel - Blood

2.43

2.15

15.7

3.5

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

4.31

2.09

4.3

1.4

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

2.76

2.06

4.3

3.0

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

3.62

2.03

1.4

1.3

—

(3026493) Urate [Moles/volume] in Serum or Plasma

2.27

2.02

4.4

2.6

361.3

5267.1

umol/l

0.50

(3021601) Nitrite [Presence] in Urine by Test strip

179

2.04

1.94

7.2

4.7

0.0

estimate

—

(3030981) Hyaline casts [#/volume] in Urine by Automated count

3.30

1.86

5.6

3.7

0.1

0.2

e6/l

—

(3020630) Protein [Mass/volume] in Serum or Plasma

3.30

1.86

1.6

1.7

60.6

65.2

g/l

—

(3035350) Ketones [Presence] in Urine by Test strip

175

1.97

1.76

5.1

3.5

0.0

estimate

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

2.30

1.76

2.9

1.9

—

(3009261) Glucose [Presence] in Urine by Test strip

184

1.96

1.76

5.2

3.6

0.0

estimate

—

(3008037) Lactate [Moles/volume] in Venous blood

4.09

1.75

4.6

1.9

1.4

1.3

mmol/l

—

(3038515) Glucose [Moles/volume] in Venous blood

4.09

1.75

4.6

1.9

10.4

6.9

mmol/l

—

(3030306) Epithelial cells.non-squamous [#/volume] in Urine by Automated count

2.23

1.57

2.3

2.5

1.5

0.7

e6/l

—

(3021589) Normoblasts [#/volume] in Blood

155

1.90

1.55

17.8

8.3

0.0

e9/l

0.48

125

(40768797) Stomach Pathology biopsy report

2.40

1.49

1.1

—

(3004588) Protein electrophoresis panel - Serum or Plasma

2.91

1.47

1.0

1.5

—

(1761482) Bacteria [#/volume] in Urine by Culture

3.31

1.47

5.8

3.6

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

2.16

1.47

3.1

2.7

1.4

1.5

e6/l

—

(40760892) CBC W Ordered Manual Differential panel - Blood

2.22

1.37

15.0

4.1

—

(3000067) Parathyrin.intact [Mass/volume] in Serum or Plasma

2.66

1.34

3.2

5.8

71.5

99.2

ng/l

—

(3023368) Bacteria identified in Blood by Culture

119

1.87

1.32

5.5

4.1

—

(3032080) INR in Blood by Coagulation assay

171

1.78

1.31

35.8

11.6

1.8

1.5

inr

—

(36304419) Bacteria [Presence] in Urine

104

1.88

1.26

2.3

2.8

—

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

1.90

1.26

1.7

1.8

1.4

1.3

mmol/l

0.25

(3023081) Carboxyhemoglobin/Hemoglobin.total in Blood

2.77

1.24

3.6

2.0

1.8

1.5

—

(3007930) Methemoglobin/Hemoglobin.total in Blood

2.77

1.24

3.6

2.0

0.6

0.9

—

(3016417) Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma

2.13

1.04

1.4

33.6

27.1

u/l

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

1.94

1.02

2.1

1.5

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

164

1.65

1.00

1.7

2.0

86.0

83.3

pmol/l

0.12

(40761536) Microorganisms panel - Urine sediment

2.11

0.89

4.0

3.2

—

(3029937) Albumin [Presence] in Urine by Test strip

1.70

0.89

4.3

3.7

0.0

estimate

—

(43055554) Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation

2.03

0.87

5.3

2.4

1.2

2.0

mmol/l

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

366

1.59

0.84

25.6

13.1

76.4

72.2

ml/min/173m2

0.46

292

(3002173) Hemoglobin [Mass/volume] in Arterial blood

1.97

0.84

1.8

7.1

108.0

121.2

g/l

—

(3022145) Colonoscopy Study observation

1.91

0.81

1.5

1.2

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.00

0.81

0.0

1.6

—

(3022313) Gas panel - Capillary blood

2.27

0.78

6.0

2.5

—

(3004119) Hemoglobin [Mass/volume] in Venous blood

2.27

0.78

4.6

2.3

131.6

128.5

g/l

—

(3041096) Erythrocytes [Presence] in Urine by Automated

111

1.60

0.76

6.1

3.1

—

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

1.85

0.74

1.4

1.6

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

1.80

0.73

1.1

1.5

—

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

2.00

0.72

1.0

1.5

—

(3022621) pH of Urine by Test strip

1.79

0.65

2.2

3.0

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.64

0.64

3.6

—

(3012095) Magnesium [Moles/volume] in Serum or Plasma

1.65

0.63

6.8

1.9

0.7

0.8

mmol/l

—

(3013512) EKG study

134

1.49

0.62

8.4

4.0

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

144

1.46

0.60

5.4

3.5

—

(3002032) Base excess in Venous blood by calculation

1.55

0.53

4.3

3.9

2.9

2.5

mmol/l

—

(3012544) pH of Venous blood

1.55

0.53

4.3

4.0

—

(3020564) Creatinine [Moles/volume] in Serum or Plasma

417

1.42

0.49

34.4

16.0

83.3

88.6

umol/l

0.68

417

(1761868) Lipid panel - Serum or Plasma

124

1.39

0.44

3.3

3.2

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

400

1.36

0.43

32.4

13.3

23.9

25.0

mg/l

0.10

311

(3019225) pH of Specimen

1.47

0.37

7.8

3.2

—

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

119

1.35

0.36

1.9

1.7

52.1

57.6

u/l

0.17

111

(3003694) ABO and Rh group [Type] in Blood

1.40

0.35

1.3

1.2

—

(3027946) Carbon dioxide [Partial pressure] in Arterial blood

1.34

0.34

1.8

6.3

4.8

4.9

kpa

—

(3027801) Oxygen [Partial pressure] in Arterial blood

1.34

0.34

1.8

6.3

10.4

9.6

kpa

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

197

1.27

0.32

2.1

2.4

—

(3022217) INR in Platelet poor plasma by Coagulation assay

0.68

0.28

16.4

28.7

—

1.4

—

(3019050) Tissue transglutaminase IgA Ab [Units/volume] in Serum

1.31

0.27

1.1

1.2

—

1.0

—

(3000963) Hemoglobin [Mass/volume] in Blood

442

1.28

0.27

43.4

18.9

131.6

137.4

g/l

1.27

427

(3019550) Sodium [Moles/volume] in Serum or Plasma

411

1.25

0.27

31.4

17.0

139.0

139.8

mmol/l

1.22

393

(3003031) Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma

1.34

0.24

2.8

1.4

1.8

—

(3026008) Bacteria identified in Urine by Culture

117

1.26

0.23

4.6

3.3

—

(3023103) Potassium [Moles/volume] in Serum or Plasma

415

1.22

0.22

31.5

16.9

4.0

mmol/l

0.06

397

(3039443) Prostate specific Ag panel - Serum or Plasma

0.00

0.21

0.0

1.3

—

(4094501)

0.00

0.21

0.0

1.1

—

(3005013) Prostate Specific Ag Free [Mass/volume] in Serum or Plasma

122

1.19

0.15

3.1

2.7

0.7

0.8

ug/l

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

171

1.16

0.15

5.9

3.5

18.0

25.6

—

(3003338) MCHC [Mass/volume]

330

1.14

0.14

39.2

16.5

332.0

332.7

g/l

0.13

325

(3035941) MCH [Entitic mass]

442

1.17

0.14

43.9

18.8

30.7

30.4

0.47

426

(3024731) MCV [Entitic volume]

442

1.17

0.14

44.0

18.7

92.2

91.2

0.75

426

(3044889) 12 lead EKG panel

282

1.13

0.12

4.8

4.5

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

387

1.10

0.07

13.7

5.1

6.1

6.2

mmol/l

0.11

341

(3012516) Albumin [Mass/volume] in Urine

139

1.10

0.06

3.7

3.2

198.8

542.7

mg/l

—

(3007220) Creatine kinase [Enzymatic activity/volume] in Serum or Plasma

139

1.10

0.06

2.3

150.5

211.0

u/l

0.53

130

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

269

1.08

0.05

4.1

3.3

15.7

14.8

pmol/l

0.75

232

(40761511) CBC panel - Blood by Automated count

410

0.93

0.04

27.7

12.5

—

(3009542) Hematocrit [Volume Fraction] of Blood

343

1.05

0.01

27.5

13.8

38.3

40.6

0.37

229

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

1.4

—

(3017895) Helicobacter pylori Ab [Units/volume] in Serum

0.00

0.0

2.2

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

0.0

1.6

—

(3026389) Candida sp identified in Specimen by Organism specific culture

0.00

0.0

1.1

—

(3023150) Myeloperoxidase Ab [Units/volume] in Serum

0.00

0.0

1.2

—

(3014271) Vancomycin [Susceptibility]

0.00

0.0

1.8

—

(3019230) Fractional oxyhemoglobin in Venous blood

0.00

0.0

3.0

—

68.0

—

(3024928) Oxygen saturation in Venous blood

0.00

0.0

4.2

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

0.00

0.0

1.0

—

(3006257) Acetylcholine receptor Ab [Moles/volume] in Serum

0.00

0.0

1.0

—

(3013566) Clostridioides difficile [Presence] in Stool by Organism specific culture

0.00

0.0

1.2

—

(42870308) Desmosome IgG Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.0

—

(3008898) HLA-B27 [Presence]

0.00

0.0

1.1

—

(46237023) Hepatitis B virus core and surface Ab and surface Ag panel - Serum

0.00

0.0

1.0

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

0.00

0.0

5.4

—

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_KAPOSI_SARCOMA_EXALLC – Kaposi sarcoma, excluding all cancers (controls excluding all cancers)

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).

NAME	C3_KAPOSI_SARCOMA_EXALLC
CONTROL_EXCLUDE	C3_CANCER\|C3_CANCER_WIDE_EXALLC
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	C46
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	C46
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

≡ Risteys

FG R12 + FR

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Kaposi sarcoma, excluding all cancers (controls excluding all cancers)

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

All original rules

Similar endpoints

Case counts by codes

Upset plot

Case counts by code for Kaposi sarcoma, excluding all cancers (controls excluding all cancers) (C3_KAPOSI_SARCOMA_EXALLC)

Summary Statistics

-FinRegistry-

-FinnGen-

Key figures

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

LabWAS

Mortality – FinRegistry

Relationships between endpoints